The adipocyte-derived secretory factor adiponectin promotes insulin sensitivity, decreases inflammation and promotes cell survival. No unifying mechanism has yet explained how adiponectin can exert such a variety of beneficial systemic effects. Here, we show that adiponectin potently stimulates a ceramidase activity associated with its two receptors, AdipoR1 and AdipoR2, and enhances ceramide catabolism and formation of its antiapoptotic metabolite-sphingosine-1-phosphate (S1P)-independently of AMP-dependent kinase (AMPK). Using models of inducible apoptosis in pancreatic beta cells and cardiomyocytes, we show that transgenic overproduction of adiponectin decreases caspase-8-mediated death, whereas genetic ablation of adiponectin enhances apoptosis in vivo through a sphingolipid-mediated pathway. Ceramidase activity is impaired in cells lacking both adiponectin receptor isoforms, leading to elevated ceramide levels and enhanced susceptibility to palmitate-induced cell death. Combined, our observations suggest a unifying mechanism of action for the beneficial systemic effects exerted by adiponectin, with sphingolipid metabolism as its core upstream signaling component.
a r t i c l e s Adiponectin, encoded by the Adipoq gene, is emerging as a protein hormone with insulin-sensitizing, anti-inflammatory and antiapoptotic functions. However, the underlying mechanistic basis for these pleiotropic actions are unknown. Adiponectin is released by adipocytes and targets a multitude of different cell types. Prominent target cells are hepatocytes, cardiac myocytes, pancreatic beta cells and podocytes. The genes encoding two related receptors, AdipoR1 and AdipoR2, have been cloned, and these receptors may mediate many of the actions of adiponectin 1 . Overexpression of adiponectin from adipose tissue results in improvements in systemic insulin sensitivity 2, 3 , whereas loss of function of adiponectin or its receptors results in decreased insulin sensitivity 4, 5 . Activation of AMPK has been reported as a downstream readout for these receptors [6] [7] [8] ; however, the mechanisms inducing this activity and the dependence on AMPK activation for adiponectin-mediated improvements in glucose homeostasis have not been clarified.
Similar responses have been reported upon acute exposure of mice to recombinant adiponectin. However, the physiological responses of the mice vary greatly, dependent on the source, quality and complex formation of the recombinant protein 9 . Many reports take advantage of bacterially produced globular adiponectin, which can activate AMPK in muscle by mechanisms that may involve calmodulindependent protein kinase kinase (CAMKK) 8 . However, there is no convincing evidence that there is an endogenous globular form similar to this recombinant version under normal physiological conditions. Rather, to obtain adiponectin that is more comparable to the endogenous multimeric adiponectin complexes, the recombinant material must be generated in mammalian cells. In contrast to the globular form, these higher-molecular-weight complexes tend not to be associated with muscle, but rather abundantly accumulate in the liver and other tissues 10 .
Sphingolipids, such as ceramide and glucosylceramides, are an important class of bioactive lipids that are produced by a ubiquitous biosynthetic pathway initiated by the condensation of palmitoylcoenzyme A (CoA) and serine 11 . Ceramide and its glycerol-based counterpart, diacylglycerol (DAG), correlate with impaired insulin action in muscle 12, 13 . Whereas DAG-mediated insulin resistance has been linked with protein kinase C-θ activation [14] [15] [16] , ceramide impairs insulin signaling through activation of protein phosphatase 2A 17, 18 and protein kinase C-ζ [19] [20] [21] . In addition to impairments in insulin signaling, aberrant accumulation of ceramides, glucosylceramides and GM3 gangliosides has been implicated in many metabolic processes including atherosclerosis, beta cell decompensation and lipotoxic heart failure (reviewed in ref. 12) . In contrast, the phosphorylated sphingoid base sphingosine 1-phosphate (S1P) is a potent inducer of proliferation and inhibitor of apoptosis 22 . Given the opposing nature a r t i c l e s of ceramide and S1P, and the simple two-step process that converts one lipid into the other, speculation has arisen that the dynamic ratio of ceramide to S1P may constitute a physiological rheostat regulating many cellular processes 22 .
Here, we demonstrate that adiponectin exerts its beneficial metabolic effects through a lowering of cellular ceramide, mediated by activation of its cognate receptors AdipoR1 and AdipoR2. These receptors confer ceramidase activity that can be further enhanced by adiponectin. Our data establish a connection between the vast literature on the systemic effects of adiponectin and the observations that link altered levels of ceramides and its metabolites with changes in insulin sensitivity, inflammation and survival.
RESULTS
Adiponectin lowers ceramide levels independent of AMPK We examined the relationship between adiponectin and sphingolipid metabolism in several models of insulin resistance. The leptindeficient Lep ob/ob mouse, with its characteristic hyperlipidemic profile that is associated with hypoadiponectinemia, offers an ideal setting to study this phenomenon. Compared to lean littermates, Lep ob/ob livers had elevated ceramide levels. The administration of recombinant adiponectin effectively reduced hepatic ceramide content ( Fig. 1a) . Adiponectin universally decreased all hepatic ceramide and dihydroceramide species, showing no discrimination for the acyl chain length or saturation of ceramides ( Supplementary Fig. 1a) .
In euglycemic clamp studies in Lep ob/ob mice, adiponectin injections caused an increase in the glucose infusion rate within 30-40 min ( Fig. 1b) , indicating an improvement in whole-body insulin sensitivity. The ceramide-lowering effects of adiponectin happened within the same time frame ( Supplementary Fig. 1b ). Consistent with our previous studies 4,23,24 , hepatic insulin sensitivity (but not muscle insulin sensitivity) was improved as demonstrated by an adiponectinmediated lowering of hepatic glucose output during the clamp ( Supplementary Fig. 1c,d) . These results could not be explained by differences between blood glucose levels or plasma insulin concentrations during the clamps ( Supplementary Fig. 1e,f) .
We also tested whether adiponectin can exert similar effects in the pathophysiologically more relevant model of a high-fat diet (HFD) feeding regimen. A HFD increased hepatic ceramide content, whereas the acute administration of full-length recombinant adiponectin normalized ceramide levels ( Fig. 1c) . Acute adiponectin treatment did not lower diacylglycerol in either obese model ( Supplementary  Fig. 2a,b) . The ceramide-lowering effects of recombinant adiponectin in the liver were cell autonomous: in cultured H4iie hepatocytes, treatment with palmitate plus PBS induced a ceramide accumulation 2.19 ± 0.07 times that in cells treated with the control fatty acid-free BSA plus PBS, whereas treatment with palmitate plus adiponectin reduced this ceramide accumulation to 1.33 ± 0.09 times that of the control BSA plus adiponectin (P < 0.05, n = 6 from three separate experiments); by contrast, diacylglycerol remained elevated (a factor of 6.42 ± 0.16 versus 6.19 ± 0.26; means ± s.e.m.).
Mice transgenically overexpressing adiponectin remained insulin sensitive after HFD, whereas mice lacking adiponectin showed an enhanced degree of insulin resistance (Fig. 1d) . The hepatic ceramide content in the various adiponectin models mirrored the degree of systemic insulin resistance in these models, with adiponectinoverexpressing mice showing the lowest hepatic ceramide content, and adiponectin-null mice containing considerably higher levels of ceramide in their livers after HFD exposure ( Fig. 1e) .
We tested the role of AMPK on adiponectin-mediated ceramide depletion using mice that conditionally lack serine/threonine kinase 11 (Stk11, also known as Lkb1), the upstream kinase responsible for Figure 1 Adiponectin rapidly lowers hepatic ceramide content and improves glucose homeostasis. (a) Total ceramide levels from liver of leptin-deficient (ob/ob) mice after 60-min intravenous (i.v.) treatments with full-length adiponectin (Adn, 2 mg kg −1 ) or PBS (n = 6 per group). (b) Glucose infusion rates during hyperinsulinemiceuglycemic clamps performed on conscious unrestrained ob/ob mice before and after a bolus of Adn (2 mg kg −1 , i.v.) or PBS (n = 5 per group). (c) Total ceramide levels from livers of mice with diet-induced obesity after 60-min treatments with full-length Adn (2 mg kg −1 , i.v.) or PBS (n = 9 per group). AMPK activation. Injection of adenovirally encoded Cre recombinase into mice with loxP-flanked Lkb1 (Lkb1 fl/fl mice) eliminated LKB1 from liver and decreased AMPK phosphorylation, as compared to that in GFP adenovirus-treated control mice ( Fig. 1f) . Injection of full-length recombinant adiponectin did not alter AMPK-mediated phosphorylation of acetyl-CoA carboxylase (ACC) in Lkb1 −/− livers. Furthermore, LKB1 expression in cardiac or skeletal muscle was not affected under these conditions ( Supplementary Fig. 2c ). As previously reported for wild-type mice, adiponectin triggered a lowering of glucose in Lkb1 fl/fl mice 24 . Although Lkb1 −/− mice have elevated basal glucose levels, injection of adiponectin also was highly effective at lowering circulating glucose ( Fig. 1g) . Although adiponectin can activate AMPK under some conditions, it was able to normalize glucose levels independently of the kinase. Quantification of sphingolipids indicated that adiponectin reduced ceramide and glucosylceramide in the livers of wild-type and Lkb1 −/− mice, but did not affect GM3 ganglioside abundance ( Fig. 1h) . Altered gene expression levels of some key components of the ceramide synthesis pathway and increased adiponectin receptor expression likely contributed to an altered basal level of ceramide and slight differences in the effectiveness of adiponectin ( Supplementary Fig. 2d ).
Antiapoptotic effects of adiponectin on cardiac myocytes
We have previously described several models where we can conditionally induce apoptosis in selected cell types 25, 26 . These mice express a target cell-specific transgene that comprises a cassette encoding a fusion protein consisting of procaspase-8 and a mutated FK506binding protein (FKBP) dimerization domain (referred to as "ATTAC" mice, for "apoptosis through targeted activation of caspase-8"). Injection of the compound AP20187, which binds to the FKBP domains and thereby forces dimerization, results in a proapoptotic cascade identical to the endogenous caspase 8-mediated apoptosis 25 but without the upstream activation of death receptors 26, 27 . We have generated an updated version of these mice that express the transgene in a cardiomyocyte-specific fashion 27 ('HEART-ATTAC' mice).
Maximal activation of this transgene through high-dose administration of AP20187 results in widespread apoptosis in the heart and death within 4 h of administration (Z.V.W. and P.E.S., unpublished data). We have performed detailed dose responses to AP20187 and have optimized the protocol such that we obtain a mean 50% survival rate 18 to 20 h after administration of AP20187 in mice expressing the transgene on a wild-type background ( Fig. 2a) . We have bred this transgene into mice with variable levels of adiponectin. Transgenic mice overexpressing adiponectin have two to three times as much adiponectin as wild type 2 , whereas mice that are heterozygous for a genetic deletion of the adiponectin locus have 60% lower circulating adiponectin 4 . We also examined the response in mice that completely lack adiponectin. The mean survival rate of the mice was dependent on the relative levels of adiponectin in the context of the HEART-ATTAC transgene ( Fig. 2a ). Elevated levels of adiponectin conferred antiapoptotic activity on the hearts of these mice, whereas mice with a reduced level or a complete lack of adiponectin were much more prone to death at the same dose of AP20187. Adiponectin levels did not affect the expression level of the transgenic cassette (data not shown). Ceramide levels and adiponectin levels were generally inversely related: elevating adiponectin levels lowered both left ventricular and plasma ceramide concentrations ( Fig. 2b) . Furthermore, adiponectin null mice had significantly higher circulating sphingomyelin than wild-type mice (2,156 ± 164 nmol ml −1 in null mice versus 1,413 ± 150 nmol ml −1 in wild type) (n = 6, P < 0.01; means ± s.e.m.), and a trend was apparent in adiponectin heterozygous mice, although it did not reach statistical significance. AP20187 did not induce cardiac ceramide accumulation ( Supplementary Fig. 3a ). Reduction of adiponectin was associated with a substantial decrease in S1P, dihydrosphingosine-1-phosphate, dihydrosphingosine and sphingosine ( Fig. 2c) .
To investigate ceramides more directly as mediators of enhanced apoptotic susceptibility in the HEART-ATTAC mice, we pretreated the mice with myriocin, an inhibitor of serine palmitoyl-CoA transferase (SPT), the key enzyme for ceramide biosynthesis. Myriocin caused a higher survival rate of the HEART-ATTAC mice due to a decrease in the concentration of ceramide. Moreover, direct administration a r t i c l e s of the S1P mimetic FTY720 caused an improved survival rate that almost equaled that of adiponectin-overexpressing HEART-ATTAC mice. Most notably, treating HEART-ATTAC mice with S1P (1 mg per kilogram body weight, intraperitoneally (i.p.)) just before AP20187 treatment prevented death in 100% of the mice tested ( Fig. 2d) .
To determine whether this result was a direct effect on cardiac myocytes or whether it might be due to systemic changes in these mice, we performed a series of in vitro experiments on primary neonatal ventricular cardiac myocytes from HEART-ATTAC transgenic mice. These cells were pretreated with either vehicle (BSA), BSA supplemented with C2-ceramide or BSA preconjugated with palmitate to enhance endogenous ceramide synthesis. Palmitate was also added in combination with myriocin to test for ceramide-independent effects of the fatty acid. Although palmitate was sufficient to induce a low rate of apoptosis in these cells, the subthreshold dose of ceramide was insufficient to promote apoptosis in the absence of AP20187. The cardiomyocytes were examined for cell survival after exposure to AP20187 or DMSO control ( Fig. 2e) . Whereas ceramide and palmitate (but not palmitate with myriocin) exacerbated AP20187-induced apoptosis, treatment with adiponectin or S1P potently enhanced cardiac myocyte survival. Though we did not observe elevated S1P in the cardiac muscle of adiponectin transgenic mice, we did detect a 21% increase in circulating S1P compared to that in wild-type mice ( Supplementary Fig. 3b ). This is consistent with previous observations that S1P is secreted into the extracellular milieu, where it acts through a family of cognate G protein-coupled receptors. As chronic exposure of hearts to exogenous S1P has been associated with increased heart growth 28 , we evaluated cardiac weights in mouse cohorts. Compared to wild-type littermates, cardiac hypertrophy was evident in 20-and 30-week-old adiponectin transgenic mice, whereas we observed no significant differences in 10-week-old mice (Supplementary Fig. 3c ).
Antiapoptotic effects of adiponectin on pancreatic beta cells
We noticed a highly specific accumulation of adiponectin in beta cells when recombinant adiponectin was injected into adiponectin null mice ( Fig. 3a) . Immunohistological staining of the pancreas for insulin and adiponectin resulted in no detectable adiponectin signal in adiponectin null mice that had not been administered adiponectin. The recombinant adiponectin accumulated with a high degree of specificity in pancreatic cells containing insulin with no detectable signal outside the endocrine pancreas.
To further define the effects of adiponectin on beta cells, we took advantage of a mouse model of inducible beta cell death, the PANIC-ATTAC mouse 26 . This mouse works under the same principles as the HEART-ATTAC mouse, but it expresses the transgene under the rat insulin promoter. Activation of the transgene results in beta cell loss and concomitant hyperglycemia ( Fig. 3) . We chose a low concentration of AP20187 that triggers only modest hyperglycemia in PANIC-ATTAC mice on a wild-type background. In contrast, under the same conditions, mice that overexpress adiponectin remained completely euglycemic ( Fig. 3b ) and retained significantly more pancreatic insulin content than wild-type mice (Fig. 3c) . Histological analysis indicated that islet area remained significantly larger; adiponectin overexpressers were partially refractory to AP20187-induced islet loss (Fig. 3f) . Whereas changes in adiponectin expression had no significant effects on islet size or insulin content in the absence of the PANIC-ATTAC transgene, the combination of ATTAC expression and adiponectin ablation resulted in substantially smaller islets ( Fig. 3f and Supplementary Fig. 4a ) and lower pancreatic insulin content (Supplementary Fig. 4b ) in male mice, even in the absence of AP20187. Hyperglycemia emerged shortly after birth and progressively increased up to 3 weeks of age (Supplementary Fig. 4c ). The relevance of adiponectin for normal beta cell function was further highlighted by impaired insulin secretion in response to arginine (Supplementary Fig. 4d ) or glucose (Supplementary Fig. 4f) , which contributed to much higher glucose excursions during glucose tolerance tests (Supplementary Fig. 4e ). Female wild-type PANIC-ATTAC mice, which have higher circulating adiponectin than their male counterparts, were more resistant to apoptosis. However, adiponectin ablation enabled AP20187-induced hyperglycemia after aggressive dosing regimens (Fig. 3d) . AP20187 administration resulted in enhanced loss of pancreatic insulin content ( Fig. 3e ) and led to smaller islets ( Supplementary Fig. 4g ) in adiponectin null mice, suggesting an increased susceptibility to apoptosis.
To test whether these effects of adiponectin on pancreatic beta cells are cell autonomous or indirect, we examined the antiapoptotic potential of adiponectin in vitro on the INS-1 pancreatic beta cell line. Addition of adiponectin lowered the frequency of palmitate-or ceramide-induced cell death (Fig. 4a) . Moreover, adiponectin prevented palmitate-induced ceramide accumulation (Supplementary Fig. 5a ). The inclusion of a sphingosine kinase inhibitor abolished the adiponectin-mediated increases in survival rates of these cells (Fig. 4b) , suggesting that adiponectin-mediated cytoprotective effects critically depend on the generation of S1P. To evaluate the role of AMPK in the antiapoptotic action of adiponectin, we overexpressed a dominant negative (K45R) mutant of AMPK or wild-type AMPK by adenoviral delivery as previously described 29 . The AMP mimetic AICAR failed to stimulate phosphorylation of acetyl-CoA carboxylase, which confirmed effective lowering of AMPK activity (data not shown). Although the dominant negative AMPK exacerbated palmitate-induced ceramide accumulation and enhanced palmitate-induced apoptosis, adiponectin still lowered ceramide levels (Supplementary Fig. 5a ) and offered marked protection against palmitate-or ceramide-induced apoptosis (Supplementary Fig. 5b) .
To examine the kinetics of ceramide metabolism in greater detail, we performed a time course of ceramide degradation upon addition of short-chain ceramide to INS-1 cells in the presence or absence of adiponectin. Coadministration of adiponectin markedly reduced endogenous long-chain ceramides (Supplementary Fig. 5c ), led to a rapid and sustained lowering of ceramides within 20 min and effectively neutralized the exogenous short-chain ceramide ( Supplementary  Fig. 5d ). Sphingolipidomic analysis revealed that adiponectin upregulated sphingosine, S1P and dihydrosphingosine-1-phosphate, consistent with a model in which adiponectin deacylates ceramide or dihydroceramide through the activation of ceramidase enzymatic activity (Supplementary Fig. 5e ).
We next chose to directly measure whether adiponectin alters cellular ceramidase activity. As the known ceramidase enzymes are classified by pH optima and homology 30 , we conducted these assays under several different pH conditions. Adiponectin potently stimulated ceramidase activity at neutral pH (pH 6.5 to 7) (Fig. 4c) . The deacylation of ceramide at neutral pH was enhanced by adiponectin in a dose-dependent manner (Supplementary Fig. 5f ). As discussed above, ceramide and its phosphorylated degradation product S1P may form a 'rheostat' that governs survival and proliferation 22 . Evaluating the effectiveness of S1P in INS-1 cells, we determined that the addition of S1P to ceramide-or palmitate-treated cells prevented apoptosis of the cells (Fig. 4d,e ).
Ceramidase activity is associated with adiponectin receptors
Expression cloning efforts resulted in the identification of two receptors, AdipoR1 and AdipoR2, that bind adiponectin 1 . The lack of these receptors causes systemic metabolic dysfunction. Mice lacking both receptors show a more pronounced metabolic dysfunction than either individual receptor knockout 7 . The detailed downstream signaling events triggered by the activation of these receptors remain to be elucidated.
AdipoR1 and AdipoR2 belong to the progesterone and adiponectin Q receptor (PAQR) family. Some PAQR family members enhance ceramidase activity 31 . HEK-293-T cells (derived from human kidney), which express the adiponectin receptors endogenously, were used as host cells for our experiments. Transfection of cDNAs encoding AdipoR1 or AdipoR2 significantly enhanced ceramidase activity compared to control transfections with vector alone, and this activity could be stimulated by the in vitro addition of adiponectin (Fig. 5a) . Similar effects were obtained upon co-transfection with an adiponectin construct (data not shown).
We took advantage of a series of conserved histidine residues that are preserved across many different ceramidases, including AdipoR1 and AdipoR2 (ref. 31) , mutating these critical histidine residues to arginines. Receptors carrying these mutations have less ceramidase activity (Fig. 5a) , although the mutations did not affect the stability (Fig. 5b) .
To better define the role of these receptors in the ceramide degradation pathway in vivo, we used adenoviral preparations carrying the AdipoR1 and AdipoR2 open reading frames that lead to an overexpression of AdipoR1 and AdipoR2 in the liver. Infection with these adenoviruses led to a doubling of receptor expression in the liver (not shown) and caused a significant increase in hepatic ceramidase activity (Fig. 5c) . Infection with either receptor normalized hepatic ceramide content after a lard-oil infusion (Fig. 5d) . Similarly, hepatic overexpression of the receptors led to an improvement in insulin sensitivity after HFD exposure (Fig. 5e) and a concomitant lowering of the HFD-induced elevation of hepatic ceramide content (Fig. 5f) .
To further evaluate the role of adiponectin receptors as mediators of adiponectin's ceramide lowering effects in vitro, we generated double knockout (DKO) mouse embryonic fibroblasts (MEFs) lacking both AdipoR1 and AdipoR2. Once in culture, these cells grew at a comparable rate to MEFs isolated from wild-type mice, had no obvious changes in morphology, nor possessed any other features distinct from those of wild-type cells under normal growth conditions. Treatment of wild-type MEFs with adiponectin stimulated ceramidase activity. However, MEFs lacking both adiponectin receptor isoforms showed impaired ceramidase activity, and adiponectin failed to enhance the activity (Fig. 6a) . Consistent with the observation that adiponectinreceptor deficient fibroblasts had lower ceramidase activity, these cells also showed diminished accumulation of S1P and dihydro-S1P (Fig. 6b) . This altered accumulation of phosphorylated sphingoid bases was evident both under basal conditions and after stimulation with palmitate; however, sphingosine and dihydrosphingosine were unaltered. Culturing wild-type MEFs with palmitate led to markedly higher ceramide than culturing them with BSA alone. Treatment with recombinant full-length adiponectin resulted in a lowering of cellular ceramide compared to vehicle treatment, as expected (Fig. 6c) . Baseline ceramide levels were significantly higher in MEFs from DKO mice, and ceramide levels further escalated upon incubation with palmitate. In contrast to wild-type MEFs, the addition of adiponectin to these cells did not reduce ceramide levels (Fig. 6c) .
To test whether these adiponectin-induced effects on ceramide levels are mediated through AMPK, we performed the same experiment with MEFs isolated from LKB1-null mice. LKB1 is essential for adiponectin-induced AMPK activation 8 . Cells derived from these mice showed a profound loss of AMPK phosphorylation on Thr172 and diminished signaling in response to typical activators of the kinase, such as AICAR 32 . In LKB1-deficient fibroblasts, exposure to palmitate enhanced ceramide accumulation, whereas addition of adiponectin lowered ceramide concentrations to the same extent as in wild-type MEFs (Fig. 6c) . The concomitant changes in ceramide and S1P levels resulting from deletion of both adiponectin receptors produced a five times greater ratio of ceramide to S1P than in wild-type cells, suggesting susceptibility to cell death. To explore these effects on cell survival, we incubated MEFs with palmitate and assayed viability. Wild-type MEFs died to a low but measurable extent under the conditions chosen, and addition of recombinant adiponectin reduced the incidence of cell death (Fig. 6d) . MEFs from DKO mice were much more susceptible to lipid-induced cell death, and adiponectin could not improve cell survival rates (Fig. 6d) . However, addition of S1P completely rescued these cells from cell death (Supplementary Fig. 6a ). Whereas MEFs isolated from LKB1 knockout mice were more susceptible to the lipotoxic effects of palmitate exposure, adiponectin increased the survival rate markedly, consistent with its prosurvival actions being largely AMPK independent. Furthermore, we tested whether the adiponectin-related effects influence membrane ceramide levels in these cells. We isolated membrane raft structures from wild-type MEFs and DKO MEFs that were either left untreated or treated with adiponectin. Membrane raft-associated ceramide content was significantly higher in the DKO MEFs and unaffected by adiponectin treatment, whereas it was lower in rafts derived from wild-type cells and further lowered by adiponectin ( Supplementary Fig. 6b ).
Although these data collectively suggest that changes in ceramide and cell survival can occur independently of AMPK, they do not preclude the possibility that AMPK activation may occur downstream or independently of ceramidase activation. We directly assessed the phosphorylation of AMPK at Thr172 after the addition of adiponectin or sphingolipid in the presence or absence of the ceramidase inhibitor D-e-MAPP ((1S),(2R)-d-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol). In cultured INS-1 beta cells, full-length wild-type adiponectin, truncated globular adiponectin, S1P and C2-ceramide all AdipoR2
Glycerol Lard oil
Normal chow HFD * promoted AMPK phosphorylation (Fig. 6e) . Ceramidase inhibition prevented AMPK phosphorylation induced by both forms of adiponectin and C2-ceramide, but did not prevent AICAR or S1P from promoting phosphorylation. Identical results were seen in cultured C2C12 myotubes, the system in which adiponectin's link to AMPK was first observed (data not shown). The activation of AMPK by C2-ceramide is perplexing, but is likely mediated by ceramide metabolism into sphingosine or S1P rather than ceramide itself. Consistent with that concept, ceramidase inhibition prevented the effect of ceramide on AMPK phosphorylation, and addition of a ceramide analog to INS-1 cells promoted a 57-fold increase in S1P (P < 0.01, n = 4).
DISCUSSION
The physiological actions of adiponectin are very diverse. For example, elevated adiponectin is correlated with improved metabolic parameters. Chronic elevation of adiponectin through either the use of a transgene or pharmacologically through treatment with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists notably enhances metabolic health in mice. Phenotypic changes in adiponectin mouse models are more marked upon exposure to a high-fat diet or when the mice are bred into the Lep ob/ob background. Clinically, adiponectin levels are an excellent systemic parameter reflecting the overall health of adipose tissue. Ceramide promotes a diverse array of activities related to metabolic disease, often in direct opposition to adiponectin 33 . Targeted disruption of ceramide or glucosylceramide accumulation improves insulin action and promotes beta cell survival, akin to the actions of adiponectin [34] [35] [36] [37] . Recent work has identified ceramide as a critical factor for toll-like receptor-4-mediated antagonism of insulin action (W.L.H. and S.A.S., unpublished data). The anti-inflammatory effects of adiponectin may therefore be directly associated with ceramide depletion.
In hepatocytes, cardiomyocytes and beta cells, our data uniformly suggest a role for adiponectin receptor-mediated ceramidase activity as a primary signaling mechanism by which the adipokine elicits its broad spectrum of effects. Recent reports have suggested that the PAQR family of receptors share homology with alkaline ceramidase and, in yeast, can confer ceramidase activity on cells lacking the only known ceramidase isoform 31 . In mammalian cells, it remains unclear whether adiponectin receptors themselves can catalyze ceramide hydrolysis or whether they sequester and induce a ceramidase upon activation. Our mutational analysis of critical residues within the receptors suggests, but does not prove, that the activity may be an integral component of the receptors themselves. Of note, the ceramidase activity associated with adiponectin shows less substrate specificity than previously studied ceramidase isoforms 38 . Collectively, these studies suggest that adiponectin receptors may serve a fundamental role in the physiological regulation of ceramide and S1P balance.
Recently, adiponectin and AdipoR1 were shown to induce extracellular calcium influx that leads to an increased PPAR-γ coactivator 1-α (PGC-1α) activity and enhanced mitochondrial biogenesis 8 . While we question the role of AMPK as an upstream intracellular mediator of adiponectin's actions in liver, we want to emphasize that the results presented here are consistent with the downstream signaling model proposed by a r t i c l e s these authors 8 . We have previously shown that mice overexpressing adiponectin show a distinct upregulation of the entire mitochondrial program 2, 3, 39 . Furthermore, they show a 'browning' (that is, an enhanced mitochondrial oxidative capacity characteristic of brown adipocytes) of their white adipose tissue. Both of these are hallmarks of enhanced PGC-1α activity in adipocytes and other tissues 40 . S1P has previously been demonstrated to activate AMPK 41 , and ample evidence in the literature couples sphingosine and S1P with calcium influx and release from the endoplasmic reticulum 42, 43 . This in turn could trigger activation of CAMKK, an established activator of AMPK 8, 44 . Our data confirm these relationships and suggest that ceramidase activity is an essential initiator of the broad spectrum of adiponectin actions. As such, the reported activation of AMPK observed in a subset of cell types may be a downstream event rather than an upstream activator of adiponectin action, mediated by a conversion of ceramides into S1P, which can also trigger an influx of calcium and CAMKK activation. The potential role of S1P in adiponectin-mediated AMPK activation suggests an explanation for the lack of adiponectin-induced AMPK activation in liver, despite effects on AMPK seen in extrahepatic tissues. S1P is secreted in high-density lipoprotein particles and is degraded in the liver 45 , driven by high expression of its degrading enzyme sphingosine phosphate lyase, which is predominantly expressed in this tissue 46 . In fact, hepatic S1P levels were below the limits for detection by mass spectrometry in our assays. In addition, work in other organisms 31, 47 suggests that the pathway from PAQR to AMPK may be through other kinases with homologs in humans, notably protein kinase A (PKA) and phosphoinositide-dependent protein kinase-1 (PDK1), both of which may be stimulated by sphingoid bases and both of which are important for energy homeostasis 41, 48 . Thus, the insulin-sensitizing effects of adiponectin on its primary target tissue, the liver, may be predominantly influenced by ceramide catabolism rather than S1P accumulation. On the basis of these findings, we would like to suggest a revised view of adiponectin signaling that has sphingolipid metabolism at its core (Fig. 6f) .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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